| 摘要 |
PCT No. PCT/GB97/01521 Sec. 371 Date Dec. 9, 1998 Sec. 102(e) Date Dec. 9, 1998 PCT Filed Jun. 6, 1997 PCT Pub. No. WO97/46238 PCT Pub. Date Dec. 11, 1997The use of compound of formula (I) in which: R1 and R2 are the same or different and each represents a hydrogen atom or a C1-C5 alkyl group; R3 represents a hydrogen atom, a C1-C6 aliphatic acyl group, a (C5-C7 cycloalkane) carbonyl group, an aromatic acyl group which is a benzoyl or naphthoyl group optionally with one or more nitro, amino, alkylamino, dialkylamino, alkoxy, halo, alkyl or hydroxy substituents, a heterocyclic acyl group having one or more oxygen, sulphur or nitrogen hetero atoms and with 4 to 7 ring atoms, an optionally halo-substituted phenylacetyl or phenylpropionyl group, a cinnamoyl group, a (C1-C6 alkoxy) carbonyl group or a benzolyloxycarbonyl group; R4 and R5 are the same or different and each represents a hydrogen atom, a C1-C5 alkyl group or a C1-C5 alkoxy group, or R4 and R5together represent a C1-C4 alkylenedioxy group; n is 1, 2, or 3; W represents the -CH2, >CO or >CH-OR6 group (in which R6 represents any one of the atoms or groups defined for R3 and may by the same as or different from R3); and Y and Z are the same or different and each represents an oxygen atom or an imino (=NH) group; or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the amelioration of inappropriate endothelial cell activation.
|
